AIHTA - Publications - Search - Tislelizumab (Tevimbra®) with chemotherapy for the first-line treatment of HER-2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma

Rothschedl, E. and Linton-Romir, N. (2025): Tislelizumab (Tevimbra®) with chemotherapy for the first-line treatment of HER-2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma. Fact Sheet Nr. 199.

[thumbnail of Fact Sheet Nr.199.pdf]
Preview
 PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
789kB

Item Type:Horizon Scanning of Medicines
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WI Digestive system > WI 250 Oesophagus
WI Digestive system > WI 300-387 Stomach
Language:English
Series Name:Fact Sheet Nr. 199
Deposited on:13 Nov 2025 17:24
Last Modified:13 Nov 2025 17:24

Repository Staff Only: item control page